ArticleCommunications biology2025
Kinase activity of DYRK family members is required for regulating primary cilium length, stability and morphology.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement.Chemical biology & drug design · 2026Review
- Targeting DYRKs in Cardiovascular Diseases: From Biological Mechanisms to Therapeutic Translation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The dual-specificity tyrosine-phoshorylation-regulated kinase (DYRK) family are multifunctional enzymes crucial for diverse cellular processes, including signaling through the primary cilium. Their dysregulation has been implicated in various cancers and developmental disorders, highlighting the need to define their interactors and cellular functions to inform targeted therapeutics. In this study, we generate the proximity interactome of DYRK3, identifying 178 proteins involved in a range of cellular processes, including primary cilium biogenesis. We then investigate the specific role of DYRK3 and its cooperation with other DYRK family members in cilium assembly and maintenance. RNAi-mediated depletion of DYRK3 and pharmacological inhibition of DYRK kinase activity using GSK-626616 (GSK) lead to elongation of the cilium, particularly its distal segment. GSK treatment also induces ciliary defects, length fluctuations, and increased ectocytosis. Co-depletion and phenotypic rescue experiments reveal that DYRK2 and DYRK3 cooperate in regulating cilium length. Moreover, inhibiting or depleting known cilium length regulators, or quantifying their ciliary levels in GSK-treated cells, reveal functional relationships of DYRKs to centriolar satellites and the IFT complex. Collectively, our findings uncover regulatory roles for DYRK3 and DYRK kinase activity in the assembly and maintenance of primary cilium with proper length, stability, and morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.